New Cancer Drugs at the Cost of Bankruptcy: Will the Oncologist Tell the Patients the Benefit in Terms of Days/Weeks Added to Life?-Reference-Cited by-同舟云学术

New Cancer Drugs at the Cost of Bankruptcy: Will the Oncologist Tell the Patients the Benefit in Terms of Days/Weeks Added to Life?

Published:2014-10-31 Issue:12 Volume:19 Page:1291-1291
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Garg Pankaj Kumar¹,Jain Bhupendra Kumar¹

Affiliation:

1. Department of Surgery, University College of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi, Delhi, India

Abstract

In addition to considerations of possible cancer treatments reducing quality of life, the cost effectiveness of such treatments must also be a factor when determining treatments. Some patients have opted for expensive new treatments, leading to high financial risk but only modest results. Oncologists must explain to patients the expected benefits of treatments in terms of absolute values to allow patients to make informed decisions.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2014-0263

Reference8 articles.

1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

2. Quality of life in the Trastuzumab for Gastric Cancer Trial;Satoh;The Oncologist,2014

3. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction;Norman;Health Technol Assess,2011

4. Cancer drugs in the United States: Justum Pretium: The just price;Kantarjian;J Clin Oncol,2013

5. Medical bankruptcy in the United States, 2007: Results of a national study;Himmelstein;Am J Med,2009

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial: Multimodal management of advanced gastric cancer;Frontiers in Oncology;2022-12-29

2. Adjuvant nivolumab for the management of pathological residual disease in esophageal or junctional tumors: a word of caution;Annals of Oncology;2021-09

3. Do we need evidence for evidence‐based medicine?;Journal of Evaluation in Clinical Practice;2021-05-08

4. Redefining the Treatment Endpoints in Oncology;The Oncologist;2021-02-12

5. Social taboos: a formidable challenge in cancer care;BMJ Case Reports;2021-01